BMY / Top Wall Street analysts favor these five dividend stocks during tumultuous times

Shares of Bristol Myers Squibb (BMY) fell Thursday after the company reported that sales of the drug maker's popular Revlimid blood cancer treatment p more_horizontal

Bristol Myers Squibb (BMY) came out with quarterly earnings of $2 per share, beating the Zacks Consensus Estimate of $1.76 per share. This compares to more_horizontal

Bristol-Myers Squibb Co. BMY, +0.87% on Thursday posted net income of $1.928 billion, or 93 cents a share, for the third quarter, up from $1.606 billi more_horizontal

Bristol Myers Squibb's revenue was in line with estimates, but fell slightly from the same period last year due to lower sales of blood cancer drug Re more_horizontal

Drugmaker Bristol Myers Squibb on Thursday pushed back by a year the time frame for its current new-product portfolio to hit $10 billion in sales as t more_horizontal

Investors are likely to focus on Opdivo's demand along with an incremental contribution from newer drugs when Bristol-Myers (BMY) reports Q3 results. more_horizontal

Bristol Myers Squibb is a large pharmaceutical company with a strong dividend yield and impressive assets. The company's recent acquisition of Mirati more_horizontal

TipRanks' analyst ranking service pinpoints Wall Street's best-performing stocks, including Cisco and Chesapeake Energy. more_horizontal